|
86 Companies |
|
137 Products |
|
137 Products |
|
85 Mechanisms of Action |
|
4 Trials |
|
2019 News |
|
| «12345678910111213...3940» |
- Actemra IV (tocilizumab) / Roche, JW Pharma
Enrollment change: Tocilizumab as Add-On Treatment For Residual Positive, Negative, and Cognitive Symptoms of Schizophrenia (clinicaltrials.gov) - Apr 22, 2016
P4, N=75, Recruiting, Sponsor: New York State Psychiatric Institute
N=50 --> 75
- Trial completion: ASCI: Social Cognition Intervention (clinicaltrials.gov) - Apr 21, 2016
P=N/A, N=105, Completed, Sponsor: VA Office of Research and Development
N=50 --> 75 Active, not recruiting --> Completed
- || Rexulti (brexpiprazole) / Lundbeck, Otsuka
Enrollment change, Trial primary completion date: Safety Follow-up Study for Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Previously Participated in a Double-blind Trial of Brexpiprazole or Placebo (clinicaltrials.gov) - Apr 19, 2016
P=N/A, N=450, Enrolling by invitation, Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
Active, not recruiting --> Completed N=360 --> 450 | Trial primary completion date: Aug 2017 --> Feb 2018
- Enrollment closed, IO biomarker, Immunomodulating: Withania Somnifera: an Immunomodulator and Anti-inflammatory Agent for Schizophrenia (clinicaltrials.gov) - Apr 14, 2016
P=N/A, N=80, Active, not recruiting, Sponsor: University of Pittsburgh
N=360 --> 450 | Trial primary completion date: Aug 2017 --> Feb 2018 Recruiting --> Active, not recruiting
- Trial primary completion date: Yoga as Cognitive Remediation in Schizophrenia (clinicaltrials.gov) - Apr 11, 2016
P=N/A, N=286, Active, not recruiting, Sponsor: Dr. Ram Manohar Lohia Hospital
Recruiting --> Active, not recruiting Trial primary completion date: Dec 2015 --> Sep 2015
- ||| APN1125 / CoMentis, Alpharmagen
Trial completion, Trial primary completion date: Safety, Tolerability, and Pharmacokinetics of Single Doses of APN1125 in Healthy Normal Subjects (clinicaltrials.gov) - Apr 8, 2016
P1, N=58, Completed, Sponsor: CoMentis
Trial primary completion date: Dec 2015 --> Sep 2015 Active, not recruiting --> Completed | Trial primary completion date: Jun 2016 --> Nov 2015
- ||| omega-3 ethylester concentrate / Generic mfg.
Enrollment change: Omega-3 Fatty Acids (Lovaza) for Second Generation Antipsychotic-Associated Hypertriglyceridemia (clinicaltrials.gov) - Apr 4, 2016
P4, N=65, Completed, Sponsor: Massachusetts General Hospital
Active, not recruiting --> Completed | Trial primary completion date: Jun 2016 --> Nov 2015 N=40 --> 65
- Trial completion, Trial primary completion date: DAAOI-1 Treatment for Treatment-resistant Schizophrenia (clinicaltrials.gov) - Mar 31, 2016
P2, N=60, Completed, Sponsor: China Medical University Hospital
N=40 --> 65 Recruiting --> Completed | Trial primary completion date: Dec 2014 --> Sep 2014
- Trial primary completion date: Social Cognition Training in Schizophrenia (clinicaltrials.gov) - Mar 29, 2016
P=N/A, N=25, Recruiting, Sponsor: Oslo University Hospital
Recruiting --> Completed | Trial primary completion date: Dec 2014 --> Sep 2014 Trial primary completion date: Dec 2016 --> Jun 2017
- Enrollment open: Home Treatment for Acute Psychiatric Care (clinicaltrials.gov) - Mar 29, 2016
P=N/A, N=500, Recruiting, Sponsor: Psychiatric Services Aargau AG
Trial primary completion date: Dec 2016 --> Jun 2017 Not yet recruiting --> Recruiting
- APN1125 / CoMentis, Alpharmagen
Trial primary completion date: Safety, Tolerability, and Pharmacokinetics of Single Doses of APN1125 in Healthy Normal Subjects (clinicaltrials.gov) - Mar 28, 2016
P1, N=50, Active, not recruiting, Sponsor: CoMentis
Not yet recruiting --> Recruiting Trial primary completion date: Jan 2016 --> Jun 2016
- Trial primary completion date: Healthy Bodies, Healthy Kids (clinicaltrials.gov) - Mar 23, 2016
P=N/A, N=126, Recruiting, Sponsor: Washington University School of Medicine
Trial primary completion date: Jan 2016 --> Jun 2016 Trial primary completion date: Oct 2015 --> Dec 2016
- Trial primary completion date: Emotional Intelligence in Schizophrenia and Bipolar-I- Disorder (clinicaltrials.gov) - Mar 22, 2016
P=N/A, N=300, Recruiting, Sponsor: Medical University Innsbruck
Trial primary completion date: Oct 2015 --> Dec 2016 Trial primary completion date: Dec 2015 --> Jun 2016
- Enrollment closed: RISE (Rehabilitation Intervention for People With Schizophrenia in Ethiopia) (clinicaltrials.gov) - Mar 21, 2016
P=N/A, N=166, Active, not recruiting, Sponsor: London School of Hygiene and Tropical Medicine
Trial primary completion date: Dec 2015 --> Jun 2016 Recruiting --> Active, not recruiting
- Trial completion, Trial primary completion date: SAFARI: Return to Work: Promoting Health and Productivity in Workers With Common Mental Disorders (clinicaltrials.gov) - Mar 21, 2016
P=N/A, N=352, Completed, Sponsor: Karolinska Institutet
Recruiting --> Active, not recruiting Active, not recruiting --> Completed | Trial primary completion date: May 2015 --> Oct 2015
- Enrollment closed, Trial primary completion date: The Partners Genetics Collaborative Study of Schizophrenia (clinicaltrials.gov) - Mar 19, 2016
P=N/A, N=500, Active, not recruiting, Sponsor: Massachusetts General Hospital
Active, not recruiting --> Completed | Trial primary completion date: May 2015 --> Oct 2015 Recruiting --> Active, not recruiting | Trial primary completion date: Oct 2015 --> Oct 2016
- Kuvan (sapropterin) / BioMarin, Daiichi Sankyo
Trial primary completion date: Kuvan in People With Schizophrenia and Schizoaffective Disorder (clinicaltrials.gov) - Mar 18, 2016
P1/2, N=60, Suspended, Sponsor: New York State Psychiatric Institute
Recruiting --> Active, not recruiting | Trial primary completion date: Oct 2015 --> Oct 2016 Trial primary completion date: Feb 2016 --> Jun 2016
- olanzapine / Generic mfg., sertraline / Generic mfg.
Trial primary completion date: STOP-PD: Sustaining Remission of Psychotic Depression (clinicaltrials.gov) - Mar 18, 2016
P4, N=392, Recruiting, Sponsor: Weill Medical College of Cornell University
Trial primary completion date: Feb 2016 --> Jun 2016 Trial primary completion date: Mar 2017 --> Aug 2017
- Trial primary completion date: Neurobiology of a Mutation in Glycine Metabolism in Psychotic Disorders (clinicaltrials.gov) - Mar 16, 2016
P2, N=2, Enrolling by invitation, Sponsor: Mclean Hospital
Trial primary completion date: Mar 2017 --> Aug 2017 Trial primary completion date: Nov 2015 --> Nov 2016
- carbidopa/levodopa / Generic mfg.
Trial completion, Enrollment change, Trial primary completion date: Antipsychotic Augmentation With L-Dopa (clinicaltrials.gov) - Mar 15, 2016
P2, N=13, Completed, Sponsor: Centre for Addiction and Mental Health
Trial primary completion date: Nov 2015 --> Nov 2016 Recruiting --> Completed | N=24 --> 13 | Trial primary completion date: Sep 2016 --> Dec 2015
- Trial primary completion date: A Trial of Folate With B12 in Patients With Schizophrenia With Residual Symptoms in Ethiopia (clinicaltrials.gov) - Mar 14, 2016
P4, N=240, Recruiting, Sponsor: Massachusetts General Hospital
Recruiting --> Completed | N=24 --> 13 | Trial primary completion date: Sep 2016 --> Dec 2015 Trial primary completion date: Jun 2016 --> Jun 2017
- Trial primary completion date, IO biomarker, Immunomodulating: Withania Somnifera: an Immunomodulator and Anti-inflammatory Agent for Schizophrenia (clinicaltrials.gov) - Mar 10, 2016
P=N/A, N=80, Recruiting, Sponsor: University of Pittsburgh
Trial primary completion date: Jun 2016 --> Jun 2017 Trial primary completion date: Apr 2016 --> Jul 2016
- | Korlym (mifepristone) / Corcept Therap
Enrollment change: A Study of Mifepristone vs. Placebo in the Treatment of Patients With Major Depression With Psychotic Features (clinicaltrials.gov) - Mar 9, 2016
P3, N=292, Terminated, Sponsor: Corcept Therapeutics
Trial primary completion date: Apr 2016 --> Jul 2016 N=450 --> 292
- Trial completion, Enrollment change, Trial primary completion date: The Effect of Nitric Oxide on Spatial Working Memory in Patients With Schizophrenia - Pilot Study (clinicaltrials.gov) - Mar 9, 2016
P1, N=21, Completed, Sponsor: King's College London
N=450 --> 292 Recruiting --> Completed | N=30 --> 21 | Trial primary completion date: Aug 2016 --> Feb 2016
- Trial completion, Trial primary completion date: Decreasing Risk of Coronary Artery Disease in Schizophrenia by Omega-3 Fatty Acid Supplementation (clinicaltrials.gov) - Mar 9, 2016
P2, N=57, Completed, Sponsor: University of Pittsburgh
Recruiting --> Completed | N=30 --> 21 | Trial primary completion date: Aug 2016 --> Feb 2016 Active, not recruiting --> Completed | Trial primary completion date: Dec 2014 --> Dec 2015
- Trial completion: Supported Employment: Motivational Enhancement for Entry and Outcome (clinicaltrials.gov) - Mar 8, 2016
P2, N=168, Completed, Sponsor: VA Office of Research and Development
Active, not recruiting --> Completed | Trial primary completion date: Dec 2014 --> Dec 2015 Active, not recruiting --> Completed
- Trial completion, Trial primary completion date: Mental Health Engagement Network (MHEN) (clinicaltrials.gov) - Mar 7, 2016
P=N/A, N=400, Completed, Sponsor: Lawson Health Research Institute
Active, not recruiting --> Completed Not yet recruiting --> Completed | Trial primary completion date: Dec 2013 --> Jun 2014
- Enrollment change: Efficacy Study of GA (clinicaltrials.gov) - Mar 4, 2016
P=N/A, N=33, Completed, Sponsor: H
Not yet recruiting --> Completed | Trial primary completion date: Dec 2013 --> Jun 2014 N=47 --> 33
- Clopixol (zuclopenthixol) / Lundbeck, Serlect (sertindole) / Lundbeck, Abbott
Enrollment closed, Trial primary completion date: Evaluation of the Necessity of Long-term Pharmacological Treatment With Antipsychotics in Schizophrenic Patients (clinicaltrials.gov) - Mar 1, 2016
P4, N=25, Active, not recruiting, Sponsor: Technische Universit
N=47 --> 33 Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2016 --> May 2016
- sodium valproate / Generic mfg.
Trial primary completion date: Pilot Trial of Valproate as Adjunctive Treatment for Toxoplasma Gondii Infection in Early Course Schizophrenia (clinicaltrials.gov) - Feb 29, 2016
P4, N=100, Enrolling by invitation, Sponsor: University of Pittsburgh
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2016 --> May 2016 Trial primary completion date: Feb 2016 --> Aug 2016
- Trial primary completion date: The Effect of Nitric Oxide on Spatial Working Memory in Patients With Schizophrenia - Pilot Study (clinicaltrials.gov) - Feb 29, 2016
P1, N=30, Recruiting, Sponsor: King's College London
Trial primary completion date: Feb 2016 --> Aug 2016 Trial primary completion date: Aug 2015 --> Aug 2016
- Trial primary completion date: Microfinance Intervention to Improve Health of Trauma Survivors in DRC (clinicaltrials.gov) - Feb 29, 2016
P=N/A, N=878, Active, not recruiting, Sponsor: Johns Hopkins University
Trial primary completion date: Aug 2015 --> Aug 2016 Trial primary completion date: Dec 2015 --> Apr 2016
- ||||||| NN1213 / Novo Nordisk
Trial completion: A Safety and Tolerability Study of Paliperidone Palmitate Injected in the Shoulder or the Buttock Muscle in Patients With Schizophrenia (clinicaltrials.gov) - Feb 27, 2016
P3, N=253, Completed, Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Trial primary completion date: Dec 2015 --> Apr 2016 No longer recruiting --> Completed
- paliperidone extended release / Generic mfg.
Trial completion: Trial Evaluating Paliperidone Extended-Release (ER) Tablets Versus Placebo on Sleep in Schizophrenia Patients (clinicaltrials.gov) - Feb 27, 2016
P2, N=5, Completed, Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
No longer recruiting --> Completed Recruiting --> Completed
- ||||||| NN1213 / Novo Nordisk
Trial completion: Efficacy and Safety of a Long Acting Anti-Psychotic Versus Placebo in Patients With Schizophrenia (clinicaltrials.gov) - Feb 27, 2016
P3, N=518, Completed, Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting --> Completed No longer recruiting --> Completed
- ||||||| risperidone / Generic mfg.
Trial completion: Investigate Risperidone for the Treatment of Schizophrenia in Adolescents (clinicaltrials.gov) - Feb 27, 2016
P3, N=160, Completed, Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
No longer recruiting --> Completed Recruiting --> Completed
- ||||||| paliperidone extended release / Generic mfg.
Trial completion: A Study of Effectiveness and Safety of Paliperidone Extended-release (ER) Tablets in the Prevention of Recurrence in Adult Patients With Schizophrenia. (clinicaltrials.gov) - Feb 27, 2016
P3, N=111, Completed, Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting --> Completed Recruiting --> Completed
- ||||||| paliperidone extended release / Generic mfg.
Trial completion: Safety Study With Paliperidone ER Extended-Release (ER) Tablets in Geriatric Patients With Schizophrenia (clinicaltrials.gov) - Feb 27, 2016
P3, N=114, Completed, Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting --> Completed No longer recruiting --> Completed
- ||||||| paliperidone extended release / Generic mfg., olanzapine / Generic mfg.
Trial completion: Trial Evaluating Three Fixed Doses of Paliperidone Extended-Release (ER) Tablets and Olanzapine in the Treatment of Patients With Schizophrenia (clinicaltrials.gov) - Feb 27, 2016
P3, N=619, Completed, Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
No longer recruiting --> Completed Active, not recruiting --> Completed
- ||||||| paliperidone extended release / Generic mfg., olanzapine / Generic mfg.
Trial completion: Trial Evaluating Three Fixed Dosages of Paliperidone Extended-Release (ER) Tablets and Olanzapine in the Treatment of Patients With Schizophrenia (clinicaltrials.gov) - Feb 27, 2016
P3, N=630, Completed, Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||||||| NN1213 / Novo Nordisk
Trial completion: A Study of the Effectiveness and Safety of Galantamine Hydrobromide on Cognitive Impairment in Patients With Schizophrenia. (clinicaltrials.gov) - Feb 27, 2016
P3, N=107, Completed, Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Active, not recruiting --> Completed No longer recruiting --> Completed
- || topiramate / Generic mfg.
Trial completion: A Study to Evaluate the Safety and Effectiveness of Topiramate Compared to Placebo in the Treatment of Patients With Bipolar I Disorder (clinicaltrials.gov) - Feb 27, 2016
P3, N=13, Completed, Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
No longer recruiting --> Completed Terminated --> Completed
- ||||||| Risperdal Consta (risperidone depot formulation) / J&J
Trial completion: A Study to Assess Safety and Tolerabiltiy Associated With a Switch From Oral Antipsychotic Medications to Long-acting Injectable Risperidone in Patients With Schizophrenia. (clinicaltrials.gov) - Feb 27, 2016
P3, N=141, Completed, Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Terminated --> Completed No longer recruiting --> Completed
- ||||||| risperidone / Generic mfg.
Trial completion: Efficacy and Safety of Risperidone Compared With Placebo in the Treatment of Psychotic Symptoms in Patients With Alzheimer's Disease (clinicaltrials.gov) - Feb 27, 2016
P3, N=473, Completed, Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
No longer recruiting --> Completed No longer recruiting --> Completed
- ||||||| risperidone / Generic mfg.
Trial completion: The Efficacy and Safety of Risperidone in the Treatment of Adolescents With Schizophrenia (clinicaltrials.gov) - Feb 27, 2016
P3, N=279, Completed, Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
No longer recruiting --> Completed Recruiting --> Completed
- | NN1213 / Novo Nordisk
Trial completion: Trial of D-Cycloserine in Schizophrenia (clinicaltrials.gov) - Feb 27, 2016
P3, N=60, Completed, Sponsor: Massachusetts General Hospital
Recruiting --> Completed No longer recruiting --> Completed
- | Chantix (varenicline) / Pfizer
Enrollment closed, Phase classification: Effect of Varenicline on Cognitive Function in Cigarette Smokers With Schizophrenia (clinicaltrials.gov) - Feb 27, 2016
P2, N=40, Active, not recruiting, Sponsor: Centre for Addiction and Mental Health
No longer recruiting --> Completed Recruiting --> Active, not recruiting | Phase classification: PN/A --> P2
- Trial primary completion date, Adverse events: Monitoring and Management for Metabolic Side Effects of Antipsychotics (clinicaltrials.gov) - Feb 24, 2016
P=N/A, N=103, Active, not recruiting, Sponsor: VA Office of Research and Development
Recruiting --> Active, not recruiting | Phase classification: PN/A --> P2 Trial primary completion date: Dec 2014 --> Mar 2016
- Trial completion, Enrollment change: Oxytocin as Adjunctive Therapy for Schizophrenia (clinicaltrials.gov) - Feb 24, 2016
P2, N=32, Completed, Sponsor: IRCCS Centro San Giovanni di Dio Fatebenefratelli
Trial primary completion date: Dec 2014 --> Mar 2016 Active, not recruiting --> Completed | N=80 --> 32
- ||| osoresnontrine (BI 409306) / Boehringer Ingelheim
Enrollment closed: A Study to Investigate the Efficacy, Safety and Tolerability of Four Different Doses of BI 409306 Compared to Placebo Given for 12 Weeks in Patients With Schizophrenia on Stable Antipsychotic Treatment. (clinicaltrials.gov) - Feb 24, 2016
P2, N=516, Active, not recruiting, Sponsor: Boehringer Ingelheim
Active, not recruiting --> Completed | N=80 --> 32 Recruiting --> Active, not recruiting